Clinical information of patients with apoptosis-proficient and apoptosis-resistant ALL tumors
ALL . | Age at diagnosis, y . | WBC count at diagnosis, × 109/L . | Length of first CR, mo . | Clinical outcome . | Prognostic cytogenetic abnormality . |
---|---|---|---|---|---|
Apoptosis-proficient | |||||
32 | 12 | 210 | 56 | CR | — |
33 | 7 | 195 | 10 | R | — |
69 | 4 | 19 | 11 | CR | Hyperdiploid (55) |
70 | 6 | 56 | 11 | Regimen change | — |
74 | 2 | 7 | 62 | CR | Hyperdiploid (55) |
12 | 4 | 96 | 19 | R | — |
2 | 7 | 49 | 41 | CR | t(12;21) |
72 | 3 | 16 | 8 | CR | Hyperdiploid (58-59) |
90 | 2 | 11 | 0 | CR | Hyperdiploid (56) |
91 | 7 | 7 | 4 | CR | Hyperdiploid (57) |
92 | 6 | 47 | 0 | CR | t(12;21) |
86 | 11 | 4 | 1 | D | Hyperdiploid (55) |
88 | 5 | 6 | 1 | CR | — |
76 | 5 | 8 | 36 | CR | TEL-AML ×2 |
17 | 3 | 12 | 34 | CR | t(12;21) |
75 | 9 | 330 | 7 | CR | — |
71 | 2 | 37 | 24 | CR | Hyperdiploid (54-56) |
34r | 3 | 41 | 65 | R | Hyperdiploid (58) |
42r | 3 | 68 | 33 | R | — |
89r | 15 | 3 | 35 | R | Hyperdiploid (53) |
21r | 15 | 55 | 9 | R | — |
Apoptosis-resistant (normal p53 response) | |||||
20 | 18 | 118 | 42 | CR (BMT as standard) | — |
24 | 4 | 15 | 28 | Regimen change | TEL-AML 1(complex translocation) |
53 | 12 | 106 | 11 | R | — |
9 | 10 | 6 | 56 | CR | t(12;21) |
27 | 15 | 13 | 59 | CR | t(1;19) |
78 | 15 | 18 | 9 | CR | t(12;21) |
79 | 4 | 8 | 25 | R | — |
82 | 3 | 6 | 5 | CR | Hyperdiploid (50) |
84 | 7 | 21 | 7 | CR | — |
85 | 14 | 202 | 4 | CR | — |
93 | 5 | 3 | 1 | CR | — |
80r | 3 | 35 | 41 | R | t(12;21) |
81r | 4 | 18 | 72 | R | Hyperdiploid (56) |
36r | 8 | 20 | 43 | R | t(1;19) |
83r | 4 | 237 | 19 | R | Hyperdiploid (53) |
Apoptosis-resistant (defective p53 response) | |||||
19* | 13 | 69 | 16 | R and D | — |
22† | 2 | 140 | 31 | Regimen change | t(1;19) |
77r† | 9 | 2 | 38 | R | t(12;21) |
87r† | 11 | 16 | 11 | R | Near haploid (27) |
ALL . | Age at diagnosis, y . | WBC count at diagnosis, × 109/L . | Length of first CR, mo . | Clinical outcome . | Prognostic cytogenetic abnormality . |
---|---|---|---|---|---|
Apoptosis-proficient | |||||
32 | 12 | 210 | 56 | CR | — |
33 | 7 | 195 | 10 | R | — |
69 | 4 | 19 | 11 | CR | Hyperdiploid (55) |
70 | 6 | 56 | 11 | Regimen change | — |
74 | 2 | 7 | 62 | CR | Hyperdiploid (55) |
12 | 4 | 96 | 19 | R | — |
2 | 7 | 49 | 41 | CR | t(12;21) |
72 | 3 | 16 | 8 | CR | Hyperdiploid (58-59) |
90 | 2 | 11 | 0 | CR | Hyperdiploid (56) |
91 | 7 | 7 | 4 | CR | Hyperdiploid (57) |
92 | 6 | 47 | 0 | CR | t(12;21) |
86 | 11 | 4 | 1 | D | Hyperdiploid (55) |
88 | 5 | 6 | 1 | CR | — |
76 | 5 | 8 | 36 | CR | TEL-AML ×2 |
17 | 3 | 12 | 34 | CR | t(12;21) |
75 | 9 | 330 | 7 | CR | — |
71 | 2 | 37 | 24 | CR | Hyperdiploid (54-56) |
34r | 3 | 41 | 65 | R | Hyperdiploid (58) |
42r | 3 | 68 | 33 | R | — |
89r | 15 | 3 | 35 | R | Hyperdiploid (53) |
21r | 15 | 55 | 9 | R | — |
Apoptosis-resistant (normal p53 response) | |||||
20 | 18 | 118 | 42 | CR (BMT as standard) | — |
24 | 4 | 15 | 28 | Regimen change | TEL-AML 1(complex translocation) |
53 | 12 | 106 | 11 | R | — |
9 | 10 | 6 | 56 | CR | t(12;21) |
27 | 15 | 13 | 59 | CR | t(1;19) |
78 | 15 | 18 | 9 | CR | t(12;21) |
79 | 4 | 8 | 25 | R | — |
82 | 3 | 6 | 5 | CR | Hyperdiploid (50) |
84 | 7 | 21 | 7 | CR | — |
85 | 14 | 202 | 4 | CR | — |
93 | 5 | 3 | 1 | CR | — |
80r | 3 | 35 | 41 | R | t(12;21) |
81r | 4 | 18 | 72 | R | Hyperdiploid (56) |
36r | 8 | 20 | 43 | R | t(1;19) |
83r | 4 | 237 | 19 | R | Hyperdiploid (53) |
Apoptosis-resistant (defective p53 response) | |||||
19* | 13 | 69 | 16 | R and D | — |
22† | 2 | 140 | 31 | Regimen change | t(1;19) |
77r† | 9 | 2 | 38 | R | t(12;21) |
87r† | 11 | 16 | 11 | R | Near haploid (27) |
Shown for each patient are age and WBC at diagnosis, length of first continuous remission (CR), clinical outcome (R, relapse; D, death), and prognostic cytogenetic abnormalities (—, absence of prognostic cytogenetic abnormality; number of chromosomes is given in parentheses alongside ploidy status).
TP53 mutant.
Defective activation of p53 (possible ATM inactivation).